Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Investing Activities: 2016-2025

Historic Cash from Investing Activities for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to -$246.3 million.

  • Rhythm Pharmaceuticals' Cash from Investing Activities fell 171.25% to -$246.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$146.3 million, marking a year-over-year decrease of 213.44%. This contributed to the annual value of -$48.2 million for FY2024, which is 750.36% down from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Cash from Investing Activities of -$246.3 million as of Q3 2025, which was down 555.90% from $54.0 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Cash from Investing Activities peaked at $72.5 million during Q1 2022, and registered a low of -$246.3 million during Q3 2025.
  • In the last 3 years, Rhythm Pharmaceuticals' Cash from Investing Activities had a median value of $21.2 million in 2024 and averaged -$20.1 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 662.57% in 2022, then spiked by 731.10% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at $7.2 million in 2021, then crashed by 662.57% to -$40.8 million in 2022, then soared by 155.52% to $22.6 million in 2023, then dropped by 6.55% to $21.2 million in 2024, then tumbled by 171.25% to -$246.3 million in 2025.
  • Its last three reported values are -$246.3 million in Q3 2025, $54.0 million for Q2 2025, and $24.8 million during Q1 2025.